Johnson & Johnson swallows another drugmaker in $14.6 billion deal

Johnson & Johnson swallows another drugmaker in $14.6 billion deal
Sherwood News; by J. Edward Moreno; 1/13/25
J&J has spent at least $56.5 billion on acquisitions in the past five years. Johnson & Johnson announced Monday that it would acquire drugmaker Intra-Cellular Therapies for $14.6 billion, marking its latest bid for growth via swallowing a smaller company. Intra-Cellular Therapies makes Caplyta, a drug that treats schizophrenia, bipolar disorder, and major depressive disorder. The deal comes right as generics for J&J’s blockbuster psoriasis drug Stelera are set to enter the market.